The U.S. etoricoxib market has continued its upward price trend in the first half of March 2025, following the steady rise since January. The prices are expected to keep rising in the weeks ahead as a result of shortages in supply, rising procurement prices, and high demand.

Key Takeaways

• United States prices for etoricoxib expected to keep increasing in March 2025.
• The 10% tariff hike on Chinese imports increasing the cost of procurement.
• Production increases and supply chain problems putting pressure on pricing.
• Increasing demand and drawing-in supply increasing the competitiveness of etoricoxib.

The 10% tariff hike on all Chinese imports introduced in early February has continued to push sourcing costs up and limit supply availability for Etoricoxib. Due to this, buyers are compelled to purchase stock at a higher price. Delayed deliveries from suppliers and reducing inventory levels have intensified competition for scarce shipments, putting more pressure into an already tense market.

The import-dependent American market is most susceptible to the shifting tides of global trade fundamentals. Chinese producers, being a principal source of etoricoxib, have increased their export prices taking into account the rise in production costs and strong demand globally. This has only contributed to the squeeze on procurement expenses for American purchasers, fueling further the persistent price hike. Though there has been some limited relief from declining logistical expenses, supply pressures continue to overwhelm each and every possible saving, and the momentum of the price hike for Etoricoxib remains unbroken.

Demand fundamentals have remained steady, underpinned by a recovering industrial base as well as strong pharmaceutical demand. The U.S. manufacturing PMI grew for the second month in a row, its strongest performance in a number of months, after a lengthy period of decline. This industrial recovery, coupled with improving new orders and rising production activity, has underpinned demand for etoricoxib, especially in pharmaceutical uses.

Inflationary patterns have also helped to create market dynamics for Etoricoxib. Consumer Price Index (CPI) increased 0.2% in February, which placed the annual inflation rate at 2.8%, aiding in maintaining consumer spending and sentiment. Market players' aggressive purchasing plans to offset future cost increases have contributed to the further intensification of supply scenario.

Concerns regarding future regulatory overhaul and ongoing doubts regarding trade policy have fueled the demand for Etoricoxib, so buyers are going out and buying inventory ahead of expected price gains. With supply-side restrictions remaining in place and demand holding steady, United States etoricoxib prices will keep moving higher through the remainder of the first quarter. Limited supply mixes, rising procurement costs, and steady buyer demand will continue to drive the price trend in the coming weeks, with volatility likely to persist throughout the marketplace.